Most recently, elexacaftor/tezacaftor/ivacaftor (ETI) was FDA approved for people with CF and at least one F508del-CFTR variant (the most common variant) or another variant shown to be responsive to ETI in vitro. Here, CFTR is linked to cystic fibrosis.